Deciphering the shared genetic basis of distinct cancers has the potential to elucidate carcinogenic mechanisms and inform broadly applicable risk assessment efforts. However, no studies have investigated pan-cancer pleiotropy within single, well-defined populations. We undertook novel genome-wide association studies (GWAS) and comprehensive evaluations of heritability and pleiotropy across 18 cancer types in two large, population-based cohorts: the UK Biobank 3
Introduction
The global burden of cancer is substantial, with an estimated 18.1 million individuals diagnosed each year and approximately 9.6 million deaths attributed to the disease. 1 Efforts toward cancer prevention, screening, and treatment are thus imperative, but they require a more comprehensive understanding of the underpinnings of carcinogenesis than we currently possess. While studies of twins, 2 families, 3 and unrelated populations [4] [5] [6] have demonstrated substantial heritability and familial clustering for many cancers, the extent to which genetic variation is unique versus shared across different types of cancer remains unclear.
Genome-wide association studies (GWAS) of individual cancers have identified loci associated with multiple cancer types, such as 1q32 (MDM4) 7, 8 ; 2q33 (CASP8-ALS2CR12) 9, 10 ; 3q28 (TP63) 11, 12 ; 4q24 (TET2) 13, 14 ; 5p15 (TERT-CLPTM1L) 9, 12 ; 6p21 (HLA complex) 15, 16 ; 7p15 17 ; 8q24 12, 18 ; 11q13 18, 19 ; 17q12 (HNF1B) 18, 20 ; and 19q13 (MERIT40) 21 . In addition, recent studies have tested single nucleotide polymorphisms (SNPs) previously associated with one cancer to discover pleiotropic associations with other cancer types. [22] [23] [24] [25] Consortia, such as the Genetic Associations and Mechanisms in Oncology, have looked for variants and pathways shared by breast, colorectal, lung, ovarian, and prostate cancers. [26] [27] [28] [29] [30] Comparable studies for other cancersincluding those that are less common-have yet to be conducted.
In addition to individual variants, recent studies have evaluated genome-wide genetic correlations between pairs of cancer types. [4] [5] [6] One evaluated 13 cancer types and found shared heritability between kidney and testicular cancers, diffuse large B-cell lymphoma (DLBCL) and osteosarcoma, DLBCL and chronic lymphocytic leukemia (CLL), and bladder and lung cancers. 4 Another study of six cancer types found correlations between colorectal cancer and both lung and pancreatic cancers. 5 In an updated analysis with increased sample size, the same group identified correlations of breast cancer with colorectal, lung, and ovarian cancers and of lung cancer with colorectal and head/neck cancers. 6 While these studies provide compelling evidence for shared heritability across cancers, they lack data on several cancer types (e.g., cervix, melanoma, and thyroid). Moreover, previous analyses aggregated numerous studies with case-control sampling and heterogeneous populations recruited during different time periods.
Here, we present analyses of genome-wide SNP data with respect to 18 cancer types, based on 475,312 individuals of European ancestry from two large, independent, and contemporary cohorts unselected for phenotype -the UK Biobank (UKB) and the Kaiser Permanente Genetic
Epidemiology Research on Adult Health and Aging (GERA) cohorts. We sought to detect novel risk SNPs and pleiotropic loci and variants and to estimate the heritability of and genetic correlations between cancer types. Leveraging the wealth of individual-level genetic and clinical data from both cohorts allowed us to comprehensively interrogate the shared genetic basis of susceptibility to different cancer types, with the ultimate goal of better understanding common genetic mechanisms of carcinogenesis and improving risk assessment.
Results

Genome-wide Association Analyses of Individual Cancers
We found 29 novel, independent variants that attained genome-wide significance at P<5x10 -8 upon meta-analysis ( Table 1) and an additional 12 genome-wide significant variants that were only genotyped or imputed in one cohort (Supplementary Table 1 ). There were a total of 202 novel, independent variants with a suggestive P<1x10 -6 across the 18 cancer types in the set of SNPs either meta-analyzed or analyzed in just one cohort (Supplementary Table 1 ). In addition, we detected and confirmed 280 independent signals with P<1x10 -6 identified by previous GWAS with Table 2 ).
Of the 29 novel genome-wide significant associations from the meta-analyses, 13 were in known susceptibility regions for the cancer of interest but independent of previously reported variants.
The remaining 16 were in regions not previously associated with the cancer of interest in individuals of European ancestry. Twenty-one of the 29 novel SNPs were in regions previously associated with at least one of the other cancer types evaluated in this study.
Genome-Wide Heritability and Genetic Correlation
Array-based heritability estimates across cancers ranged from h 2 =0.04 (95% CI: 0.00-0.13) for oral cavity/pharyngeal cancer to h 2 =0.26 (95% CI: 0.15-0.38) for testicular cancer ( Table 2) . For some of the cancers, our array-based heritability estimates were comparable to twin-or familybased heritability estimates but were more precise. Several were also similar to array-based heritability estimates from consortia comprised of multiple studies. For example, our estimate for testicular cancer closely matches the previous family-based estimate of heritability (h 2 =0.25; 95%
Locus-Specific Pleiotropy
We identified 43 pleiotropic regions by our linkage disequilibrium (LD) clumping procedure (Figure 1c; Supplementary Table 4) . Most were at known cancer pleiotropic loci: HLA (24 regions), 8q24 (10 regions), TERT-CLPTM1L (5 regions), and TP53 (1 region). Twenty-two of the HLA regions were associated with both cervical cancer and NHL, and the remaining two were associated with cervical and prostate cancers and, separately, NHL and prostate cancer. Six regions in 8q24 were associated with prostate and colon cancers, and four were associated with prostate and breast cancers. Of the regions in TERT-CLPTM1L, two were associated with prostate cancer and, separately, breast and testicular cancers; two were associated with melanoma and, separately, breast and bladder cancers; and the last was associated with melanoma and cervical, lung, and pancreatic cancers. The one region in TP53, indexed by rs78378222, was associated with melanoma and lymphocytic leukemia. The remaining three pleiotropic regions were in loci previously associated with at least one cancer and were indexed by rs772695095 (DIRC3 at 2q35; breast and thyroid cancers), rs11813268 (intergenic at 10q24.33; melanoma and prostate cancer), and rs6507874 (SMAD7 at 18q21.1; colon and rectal cancers).
Variant-Specific Pleiotropy
We found 137 independent variants with at least two associated cancers, the same direction of effect for all associated cancers, and an overall pleiotropic P<1x10 -6 (Supplementary Table 5) , among which 85 attained genome-wide significance (P<5x10 -8 ). Of the 137 one-directional pleiotropic SNPs, there were 45 for which the overall pleiotropic P was smaller than the P for each of the associated cancers, 17 of which attained genome-wide significance (Figure 2 ). While 134 of the total 137 were in regions that have previously been associated with cancer, 113 were associated with at least one new cancer.
We also considered omni-directional pleiotropic associations, wherein the same SNP allele was associated with increased risk for some cancers but decreased risk for others. We found 21 such variants with P<1x10 -6 , all of which were independent from one another and from the onedirectional effects (Figure 3 ; Supplementary Table 6 ). Fifteen attained genome-wide significance. There were 13 variants where the overall pleiotropic P was smaller than the P for the associated cancers, eight of which attained genome-wide significance. While 20 of the total 21
were in regions that have previously been associated with cancer, 10 were independent of known risk variants, and all 20 were associated with at least one new cancer. The SNP in a novel region (SSPN at 12q12.1) was rs10842692, which was associated with five cancers in one direction and nine cancers in the other.
The number of one-and omni-directional SNPs shared by cancer pairs ranged from four (bladder and esophagus/stomach; colon and NHL) to 32 (pancreas and prostate; leukemia and prostate) (Figure 4 ; Supplementary 
Discussion
In this first ever study to comprehensively evaluate cancer pleiotropy in cohorts unselected for phenotype, we offer multiple lines of evidence for a shared genetic basis of several cancer types.
By characterizing pleiotropy at the genome-wide, locus-specific, and variant-specific levels for more cancer sites than have ever previously been examined, we generate considerable novel insights into cancer susceptibility.
Individual GWAS of 18 cancer types yielded 29 genome-wide significant novel risk variants, 16
of which are in regions that have never previously been associated with the cancer of interest and from our cervical cancer GWAS was rs10175462 in PAX8 on 2q13, which, to our knowledge, is the first genome-wide significant cervical cancer risk SNP identified outside of the HLA region in a European ancestry population. 15 Two variants in LD with rs10175462 (rs1110839, r 2 =0.33; rs4848320, r 2 =0.34) were suggestively associated with cervical cancer in the same direction in a candidate SNP study of PAX8 expression quantitative trait loci (eQTLs) in a Han Chinese population. 32 Several GWAS findings also provided evidence of pleiotropy, in that novel risk variants for one cancer had been previously associated with one or more other cancers. For instance, rs9818780 was associated with melanoma and has been implicated in sunburn risk. 33 This intergenic variant is an eQTL for LINC00886 and METTL15P1 in skin tissue. The former gene has previously been linked to breast cancer, 34 and both genes have been implicated in ovarian cancer. 35 Beyond novel associations, our GWAS confirmed 280 independent associations from previous GWAS. We could thus feel confident using the summary statistics for subsequent analyses of cancer pleiotropy.
In evaluating pairwise genetic correlations between the 18 cancer types, we observed the strongest signal for colon and rectal cancers -an expected relationship consistent with findings from a twin study. 36 We also identified several novel cancer pairs for which the genetic correlations were nominally significant. One pair supported by previous evidence is melanoma and testicular cancer; some studies have found that individuals with a family history of the former are at an increased risk for the latter. 37, 38 Esophageal/stomach cancer was a component of five correlated pairs -with melanoma, NHL, and breast, lung, and rectal cancers. Despite some similarities between esophageal and stomach cancers, testing them as a combined phenotype may have inflated the number of correlated cancers. Our genetic correlation results contrast with previous consortia-based findings; 4-6 we did not find several correlations that they did and found others that they did not. The differences may be partly due to a smaller number of cases in our cohorts for some sites.
However, we achieved comparable or higher cancer-specific heritability estimates for breast, colon, and lung cancers, which suggests that differences in study design may also play a role.
The assessment of pleiotropy at the locus level confirmed previously reported associations at 5p15.33, HLA, and 8q24. 9, 12, 15, 16, 18 Out of the 43 pleiotropic loci that we identified, over half, all in the HLA locus, were associated with cervical cancer and NHL. The two cancers were weakly negatively correlated in the two cohorts combined and nominally significantly negatively correlated in the UKB alone (Supplementary Table 9 ). The difference may reflect better coverage and imputation of the HLA region in the UKB than in GERA. Other findings support a pleiotropic role of several loci previously associated with specific cancers in separate studies. For example, we validated previous results showing that DIRC3 is associated with breast and thyroid cancers. 14, 39 Additionally, the intergenic region surrounding rs11813268 on 10q24.33 has not been previously associated with melanoma or prostate cancer (as it was in our study), although associations with other cancers have been reported, including kidney, lung, and thyroid cancers. 35, [40] [41] [42] [43] SMAD7 has been previously linked to colorectal cancer, 44 and we confirmed its association with colon and rectal cancers separately.
Variant-specific analyses provided further evidence of locus-specific cancer pleiotropy, including validation of previously reported signals at 1q32 7, 8 and 2q33 9,10 (ALS2CR12). Interestingly, our lead 1q32 variant (rs1398148) maps to PIK3C2B and is in LD (r 2 >0.60) with known MDM4 cancer risk variants, 7, 8 suggesting that the 1q32 locus may be involved in modulating both p53-and PI3K-mediated onogenic pathways. The 158 independent SNPs identified (with an overall pleiotropic 49 Specifically, mutations that create neoantigens more likely to be recognized by specific HLA alleles are less likely to be present in tumors from patients carrying such alleles. It is thus possible that some of the positive and negative pleiotropy we identified is related to mutation type. Overall, our results reinforce the importance of the immune system playing a role in cancer susceptibility.
In contrast to the HLA region, the majority of the 8q24 pleiotropic variants had the same direction of effect for all associated cancers, implying the existence of shared genetic mechanisms driving tumorigenesis across sites. The proximity of the well-characterized MYC oncogene makes it a compelling candidate for such a consistent, one-directional effect. It could work via regulatory elements, such as acetylated and methylated histone marks. 50 Consistent with this hypothesis, we observed heritability entichment 51 for variants with the H3K27ac annotation for breast (P = 3.09x10 -4 ), colon (P = 4.44x10 -4 ), prostate (P = 2.74x10 -5 ), and rectal (P = 0.036) cancers -all of which share susceptibility variants in 8q24, according to our analyses and previous studies.
50
Considering one-directional pleiotropic effects more broadly, pathway analysis indicated that such variants are more likely to be part of canonical signaling pathways that control cell-cycle progression, apoptosis, and DNA replication stress. Dysregulation of such pathways is a hallmark of cancer.
It is important to acknowledge limitations of our analyses. First, counts for some of the cancer types were limited. Therefore, we grouped esophageal and stomach cancers and, separately, oral cavity and pharyngeal cancers. While it might have been preferable to analyze them independently, we felt that the sites had enough in common to be combined and still facilitate new discoveries.
Second, due to the complexity of the LD structure in the HLA region, it is possible that we 
Methods
Study Populations and Phenotyping
The UKB is a population-based prospective cohort of 502,611 individuals in the United Kingdom. In both cohorts, individuals with at least one recorded diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases for our analyses. For the UKB, all diagnoses described by International Classification of Diseases (ICD)-9 or ICD-10 codes were converted into ICD-O-3 codes; the KPNC Cancer Registry already included ICD-O-3 codes. We then classified cancers according to organ site using the SEER site recode paradigm. 55 We grouped all esophageal and stomach cancers and, separately, all oral cavity and pharyngeal cancers to ensure sufficient statistical power. The 18 most common cancer types (except non-melanoma skin cancer) were examined. Testicular cancer data were obtained from the UKB only due to the small number of cases in GERA.
Controls were restricted to individuals who had no record of any cancer in the relevant registries, who did not self-report a prior history of cancer (other than non-melanoma skin cancer), and, if deceased, who did not have cancer listed as a cause of death. For analyses of sex-specific cancer sites (breast, cervix, endometrium, ovary, prostate, and testis), controls were restricted to individuals of the appropriate sex.
Quality Control
For the UKB population, genotyping was conducted using either the UKB Axiom array (436,839 total; 408,841 self-reported European) or the UK BiLEVE array (49,747 total; 49,746 self-reported European). 52 The former is an updated version of the latter, such that the two arrays share over 95% of their marker content. UKB investigators undertook a rigorous quality control (QC) protocol. 52 Genotype imputation was performed using the Haplotype Reference Consortium as the main reference panel and the merged UK10K and 1000 Genomes phase 3 reference panels for supplementary data. 52 Ancestry principal components (PCs) were computed using fastPCA 56 
Genome-Wide Association Analyses
We used PLINK 63, 64 to implement within-cohort logistic regression models of additively modeled SNPs genome-wide, comparing cases of each cancer type to cancer-free controls. All models were adjusted for age at specimen collection, sex (non-sex-specific cancers only), first ten ancestry PCs, genotyping array (UKB only), and reagent kit used for genotyping (Axiom v1 or v2; GERA only).
Case counts ranged from 471 (pancreatic cancer) to 13,903 (breast cancer) in the UKB and from 162 (esophageal/stomach cancer) to 3,978 (breast cancer) in GERA (Supplementary Table 10 To determine independent signals in our union set of SNPs, we implemented the LD clumping procedure in PLINK 63,64 based on genotype hard calls from a reference panel comprised of a downsampled subset of 10,000 random UKB participants. For each cancer separately, LD clumps were formed around index SNPs with the smallest P not already assigned to another clump. To identify all potential signals, in each clump, index SNPs had a suggestive association based on P<1x10 -6 , and SNPs were added if they were marginally significant with P<0.05, were within 500kb of the index SNP, and had r 2 >0.1 with the index SNP. Index variants were determined to be novel if they were not in LD with previously reported risk variants in European ancestry populations (as described below).
To identify SNPs previously associated with each cancer type, we abstracted all genome-wide significant SNPs from relevant GWAS published through June 2018. We determined that a SNP was potentially novel if it had LD r 2 < 0.1 with all previously reported SNPs for the relevant cancer based on both the UKB reference panel and the 1000 Genomes EUR superpopulation via LDlink. 65 To confirm novelty and consider pleiotropy, an additional literature review was conducted to investigate whether these SNPs had previously been reported for the same or other cancers, including those not attaining genome-wide significance and those in non-GWAS analyses. For this additional review, we used the PhenoScanner database 66 to search for SNPs of interest and variants in LD in order to comprehensively scan previously reported associations. We then supplemented with more in-depth PubMed searches to determine if the genes in which novel SNPs were located had previously been reported for the same or other cancers.
Genome-Wide Heritability and Genetic Correlation
We used LD score regression (LDSC) of summary statistics from the union set of SNPs across both cohorts to calculate the genome-wide liability-scale heritability of each cancer type and the genetic correlation between each pair of cancer types. 67, 68 Internal LD scores were calculated using the aforementioned downsampled subset of UKB participants. To convert to liability-scale heritability, we adjusted for lifetime risks of each cancer based on SEER 2012-2014 estimates (Supplementary Table 11) . 69 LDSC was unable to estimate genetic correlations for testicular cancer with both oral cavity/pharyngeal and pancreatic cancers.
Locus-Specific Pleiotropy
Pleiotropic regions comprised of variants in LD with one another and associated with multiple cancers were constructed by LD clumping our union set of SNP-based summary statistics across all cancers. Regions were formed around index SNPs associated with any cancer with P<1x10 -6 to assess whether suggestive regions for one cancer might also be informative for another. SNPs were added to a region if they were associated with any cancer with P<1x10 -6 , were within 500kb of the index SNP, and had LD r 2 >0.5 with the index SNP. We used a larger threshold for assessing pleiotropic regions (r 2 >0.5) than for identifying truly independent signals (r 2 >0.1; above) to ensure that all SNPs within a region were in LD. If all SNPs in a region were associated with the same cancer, the region was not considered pleiotropic.
Variant-Specific Pleiotropy
We quantified one-directional and, separately, omni-directional variant-specific pleiotropy via the R package ASSET (association analysis based on subsets), which explores all possible subsets of traits for the presence of association signals in either the same or opposite directions. 70 Independent variants were determined via LD clumping, where index SNPs had a suggestive P<1x10 -6 , and
SNPs were clumped if they had P<0.05, were within 500kb of the index SNP, and had r 2 >0.1 with the index SNP. We used a suggestive significance threshold to comprehensively assess all potentially pleiotropic variants. A SNP was determined to have a one-directional pleiotropic association if the overall P was <1x10 -6 , included at least two cancers, and was not in LD with a SNP with an omni-directional pleiotropic association with a smaller overall P. A SNP was determined to have an omni-directional pleiotropic association if the overall P was <1x10 -6 , the P for each direction was <0.05, and the SNP was not in LD with a SNP with a one-directional pleiotropic association with a smaller overall P. We deconstructed omni-directional associations into cancers with risk-increasing effects and cancers with risk-decreasing effects.
The study was approved by the University of California and KPNC Institutional Review Boards, and the UKB data access committee. Manhattan plot displaying one-directional variant-specific pleiotropy, where the effect is maximized across all possible subsets of 18 cancers and assumes the same direction of effect across all selected cancers. The red dashed line represents the genome-wide significance threshold (P < 5x10 -8 ), and the black dotted line represents a suggestive threshold (P < 1x10 -6 ). Highlighted in purple are genome-wide significant loci where the overall pleiotropic P is less than all individual P for the selected cancers; details for the strongest signal at each locus are provided in the table, including the overall P and odds ratio (OR). Highlighted in green are the genome-wide significant loci where the overall pleiotropic P is greater than at least one of the individual P for the selected cancers, and highlighted in blue are loci with overall pleiotropic P < 1x10 -6 . Figure 3 . Manhattan plot displaying omni-directional variant-specific pleiotropy, where the effect is maximized across all possible subsets of 18 cancers and allows for different directions of effect for selected cancers. The red dashed line represents the genome-wide significance threshold (P < 5x10 -8 ), and the black dotted line represents a suggestive threshold (P < 1x10 -6 ). Highlighted are loci with overall pleiotropic P < 1x10 -6 , the two directional P < 0.05, and not in LD with a one-directional SNP with smaller P; loci in purple are genomewide significant loci where the overall pleiotropic P is less than all individual P for the selected cancers, loci in green are genome-wide significant loci where the overall pleiotropic P is greater than at least one of the individual P for the selected cancers, and loci in blue have P < 1x10 -6 . Details for the strongest signal at each highlighted locus are provided in the table, including overall P and odds ratio (OR). Figure 4 . The number of pleiotropic variants (of the 158 one-and omni-directional variants with overall pleiotropic P<1x10 -6 ) associated with each pair of cancers by type of pleiotropic effect for select cancer pairs. Variants were counted for a cancer pair if they were associated with both cancers using ASSET. For omni-directional variants, effects in the same direction and in opposite directions were tabulated separately. Included are all cancer pairs with any of the following cancer sites: breast, cervix, lung, melanoma, Non-Hodgkin's Lymphoma (NHL), pancreas, and prostate.
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